Over the last years, several international and multicentre clinical trials, including various Dutch sites, were conducted to evaluate the effect of two groups of potential novel HF therapeutics: namely the ARNi sacubitril-valsartan and sodium-glucose cotransporters (SGLT2) inhibitors. This evidence concerns the gene SLC5A2 and hydrops fetalis.